Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for ICON plc (ICLR:NASDAQ), powered by AI.
ICON plc is currently trading at $143.54. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for ICON plc on Alpha Lenz.
ICON plc's P/E ratio is 15.0.
“ICON plc trades at a P/E of 15.0 (undervalued) with solid ROE of 8.4%. 3Y revenue CAGR of 14.8% highlights clear growth momentum.”
Ask for details →ICON plc is a global healthcare intelligence and clinical research organization specializing in outsourced development and commercialization services for the pharmaceutical, biotechnology, and medical device sectors. Founded in Dublin, Ireland in 1990, ICON has grown into a leading contract research organization (CRO), supporting clients throughout the entire drug and device development lifecycle—from initial consulting and clinical trials (Phases I–IV) to regulatory and commercialization services. With approximately 41,900 employees in 106 locations across 55 countries as of early 2025, ICON delivers innovative solutions that help accelerate the introduction of new medical treatments worldwide. The company is recognized for its expertise in managing complex, multinational clinical projects and has established a robust presence in key global healthcare markets, including Latin America, where it has operated since 1998. ICON’s capabilities are enhanced by advanced technologies and a full-service portfolio, allowing it to assist pharmaceutical and life sciences organizations in reducing time to market, controlling costs, and maintaining high-quality standards in clinical research and product development.
“ICON plc trades at a P/E of 15.0 (undervalued) with solid ROE of 8.4%. 3Y revenue CAGR of 14.8% highlights clear growth momentum.”
Ask for details →ICON plc (ticker: ICLR) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 39,900 employees. Market cap is $11.8B.
The current price is $143.54 with a P/E ratio of 14.96x and P/B of 1.24x.
ROE is 8.44% and operating margin is 14.73%. Annual revenue is $8.3B.